Literature DB >> 26671083

Molecular spectrum of the SPAST, ATL1 and REEP1 gene mutations associated with the most common hereditary spastic paraplegias in a group of Polish patients.

Ewelina Elert-Dobkowska1, Iwona Stepniak1, Wioletta Krysa1, Marta Rajkiewicz1, Maria Rakowicz2, Anna Sobanska2, Monika Rudzinska3, Anna Wasielewska4, Jacek Pilch5, Jolanta Kubalska1, Wanda Lipczynska-Lojkowska6, Jerzy Kulczycki6, Katarzyna Kurdziel7, Agata Sikorska8, Christian Beetz9, Jacek Zaremba10, Anna Sulek11.   

Abstract

Hereditary spastic paraplegias (HSPs) consist of a heterogeneous group of genetically determined neurodegenerative disorders. Progressive lower extremity weakness and spasticity are the prominent features of HSPs resulting from retrograde axonal degeneration of the corticospinal tracts. Three genetic types, SPG3 (ATL1), SPG4 (SPAST) and SPG31 (REEP1), appear predominantly and may account for up to 50% of autosomal dominant hereditary spastic paraplegias (AD-HSPs). Here, we present the results of genetic testing of the three mentioned SPG genetic types in a group of 216 unrelated Polish patients affected with spastic paraplegia. Molecular evaluation was performed by multiplex ligation-dependent probe amplification (MLPA) and DNA sequencing. Nineteen novel mutations: 13 in SPAST, 4 in ATL1 and 2 in REEP1, were identified among overall 50 different mutations detected in 57 families. Genetic analysis resulted in the identification of molecular defects in 54% of familial and 8.4% of isolated cases. Our research expanded the causative mutations spectrum of the three most common genetic forms of HSPs found in a large cohort of probands originating from the Central Europe.

Entities:  

Keywords:  ATL1; HSP; Hereditary spastic paraplegias; REEP1; SPAST; SPG

Mesh:

Substances:

Year:  2015        PMID: 26671083     DOI: 10.1016/j.jns.2015.10.030

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  7 in total

Review 1.  Genotype-phenotype associations in hereditary spastic paraplegia: a systematic review and meta-analysis on 13,570 patients.

Authors:  Maryam Erfanian Omidvar; Shahram Torkamandi; Somaye Rezaei; Behnam Alipoor; Mir Davood Omrani; Hossein Darvish; Hamid Ghaedi
Journal:  J Neurol       Date:  2019-11-19       Impact factor: 4.849

2.  Clinical features and genotype-phenotype correlation analysis in patients with ATL1 mutations: A literature reanalysis.

Authors:  Guo-Hua Zhao; Xiao-Min Liu
Journal:  Transl Neurodegener       Date:  2017-04-04       Impact factor: 8.014

3.  Mutational Spectrum of Spast (Spg4) and Atl1 (Spg3a) Genes In Russian Patients With Hereditary Spastic Paraplegia.

Authors:  V A Kadnikova; G E Rudenskaya; A A Stepanova; I G Sermyagina; O P Ryzhkova
Journal:  Sci Rep       Date:  2019-10-08       Impact factor: 4.379

4.  Next-generation sequencing study reveals the broader variant spectrum of hereditary spastic paraplegia and related phenotypes.

Authors:  Ewelina Elert-Dobkowska; Iwona Stepniak; Wioletta Krysa; Karolina Ziora-Jakutowicz; Maria Rakowicz; Anna Sobanska; Jacek Pilch; Dorota Antczak-Marach; Jacek Zaremba; Anna Sulek
Journal:  Neurogenetics       Date:  2019-02-19       Impact factor: 2.660

5.  An allosteric network in spastin couples multiple activities required for microtubule severing.

Authors:  Colby R Sandate; Agnieszka Szyk; Elena A Zehr; Gabriel C Lander; Antonina Roll-Mecak
Journal:  Nat Struct Mol Biol       Date:  2019-07-08       Impact factor: 15.369

6.  A Japanese SPG4 Patient with a Confirmed De Novo Mutation of the SPAST Gene.

Authors:  Haitian Nan; Kensho Okamoto; Lihua Gao; Yuto Morishima; Yuta Ichinose; Kishin Koh; Masaki Hashiyada; Noboru Adachi; Yoshihisa Takiyama
Journal:  Intern Med       Date:  2020-06-09       Impact factor: 1.271

7.  ER-phagy requires the assembly of actin at sites of contact between the cortical ER and endocytic pits.

Authors:  Dongmei Liu; Muriel Mari; Xia Li; Fulvio Reggiori; Susan Ferro-Novick; Peter Novick
Journal:  Proc Natl Acad Sci U S A       Date:  2022-02-08       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.